



## News Release

### FOR IMMEDIATE RELEASE

**Investor Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
240-631-3280  
[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

**Media Contact:**

Tracey Schmitt Lintott  
Senior Vice President, Global Public Affairs  
240-631-3394  
[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)

### **EMERGENT BIOSOLUTIONS TO IMPLEMENT STOCK REPURCHASE PROGRAM FOR UP TO \$50 MILLION OF ITS COMMON STOCK**

**GAITHERSBURG, Md.—July 15, 2016**—Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the company's management to implement a stock repurchase program for up to \$50 million of the company's common stock from time to time on the open market or in privately negotiated transactions.

"The company's board and management believe that Emergent's stock price does not reflect what we consider are the fundamentals of our company's value," said Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions. "This \$50 million stock repurchase program is an opportunity to potentially create long-term shareholder value while maintaining our financial flexibility to invest in our business and to continue to pursue our acquisition strategy."

The timing, amount, and price of any repurchases will be made pursuant to one or more 10b5-1 plans. The term of the board authorization of the repurchase program is until December 31, 2017. The plan will permit shares to be repurchased when the company might otherwise be precluded from doing so under insider trading laws. The repurchase program may be suspended or discontinued at any time. Any repurchased shares will be available for use in connection with the company's stock plans and for other corporate purposes.

The repurchase program will be funded using the company's working capital. As of March 31, 2016, the company had cash and cash equivalents of approximately \$341 million. The company had approximately 39.8 million shares of common stock outstanding as of March 31, 2016.

#### **About Emergent BioSolutions**

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com). Follow us @emergentbiosolu.

### **Safe Harbor Statement**

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, prospects, plans, objectives, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates” and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including when and whether the company will be in an open period to implement a 10b5-1 trading plan; whether the 10b5-1 trading plan parameters will result in the purchase of up to \$50 million in stock; and whether such repurchases will affect the company’s stock price or long-term shareholder value. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

##